SCHEMBL260911

SCHEMBL260911

O=C(CS(=O)(=O)Cl)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
MAPK1 P28482 2/20 0.56
GSK3B P49841 2/20 0.56
HIF1A Q16665 2/20 0.56
TRPA1 O75762 1/20 0.56
MAPT P10636 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
MEN1 O00255 2/20 0.54
CYP3A4 P08684 2/20 0.54
HPGD P15428 2/20 0.54
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 1/20 0.54
ALOX15 P16050 1/20 0.54
CES1 P23141 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HSD11B1 P28845 7/20 0.53
RECQL P46063 2/20 0.53
PTPN1 P18031 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.48
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1516246 0.82 MAPK1 (0.58) ALDH1A1MAPK1GSK3BHIF1ATRPA1
SCHEMBL137832 0.80 MAPK1 (0.56) ALDH1A1MAPK1GSK3BHIF1ATRPA1
SCHEMBL7149069 0.78 MAPK1 (0.54) ALDH1A1MAPK1GSK3BHIF1ATRPA1
SCHEMBL2188285 0.78 MAPT (0.54) ALDH1A1MAPK1GSK3BHIF1ATRPA1
SCHEMBL15791249 0.78 MAPK1 (0.54) ALDH1A1MAPK1GSK3BHIF1ATRPA1
SCHEMBL113872 0.78 MAPK1 (0.54) ALDH1A1MAPK1GSK3BHIF1ATRPA1
SCHEMBL1699941 0.78 RECQL (0.58) ALDH1A1MAPK1GSK3BHIF1ATRPA1
SCHEMBL9197870 0.78 MAPK1 (0.54) ALDH1A1MAPK1GSK3BHIF1ATRPA1
SCHEMBL7868384 0.78 MAPK1 (0.54) ALDH1A1MAPK1GSK3BHIF1ATRPA1
SCHEMBL28050184 0.78 HSD11B1 (0.49) ALDH1A1MAPK1GSK3BHIF1ATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110627832-A Preparation method for synthesizing tenofovir alafenamide by oxidation method 江西农业大学 2019-12-31 CN claimed
US-12509791-B2 Formation of organic electro-grafted films on the surface of electrically conductive or semi-conductive surfaces ALCHIMEDICS (FR) 2025-12-30 US disclosed
US-12077878-B2 Formation of organic electro-grafted films on the surface of electrically conductive or semi-conductive surfaces ALCHIMEDICS (FR) 2024-09-03 US disclosed
US-20240150922-A1 FORMATION OF ORGANIC ELECTRO-GRAFTED FILMS ON THE SURFACE OF ELECTRICALLY CONDUCTIVE OR SEMI-CONDUCTIVE SURFACES ALCHIMEDICS (FR) 2024-05-09 US disclosed
US-20210025073-A1 FORMATION OF ORGANIC ELECTRO-GRAFTED FILMS ON THE SURFACE OF ELECTRICALLY CONDUCTIVE OR SEMI-CONDUCTIVE SURFACES ALCHIMEDICS (FR) 2021-01-28 US disclosed
US-10851466-B2 Formation of organic electro-grafted films on the surface of electrically conductive or semi-conductive surfaces ALCHIMEDICS (FR) 2020-12-01 US disclosed
EP-3613813-A1 FORMATION OF ORGANIC ELECTRO-GRAFTED FILMS ON THE SURFACE OF ELECTRICALLY CONDUCTIVE OR SEMI-CONDUCTIVE SURFACES Alchimer (FR) 2020-02-26 EP disclosed
CN-110627832-A Preparation method for synthesizing tenofovir alafenamide by oxidation method 江西农业大学 2019-12-31 CN disclosed
EP-2813553-B1 Formation of organic electro-grafted films on the surface of electrically conductive or semi-conductive surfaces ALCHIMER (FR) 2019-11-06 EP disclosed
US-20180251906-A1 FORMATION OF ORGANIC ELECTRO-GRAFTED FILMS ON THE SURFACE OF ELECTRICALLY CONDUCTIVE OR SEMI-CONDUCTIVE SURFACES ALCHIMEDICS (FR) 2018-09-06 US disclosed
WO-2000032556-A1 DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME SEPRACOR INC. (US) 2000-06-08 WO disclosed
WO-2000032555-A1 DERIVATIVES OF (+)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME SEPRACOR INC. (US) 2000-06-08 WO disclosed
US-5698556-A TREATING CANCER CHAN CARCY L (US) 1997-12-16 US disclosed
EP-0454463-B1 Process for producing epoxyalcohols of high optical purity ARCO CHEM TECH (US) 1997-08-13 EP disclosed
US-5278070-A Process for producing epoxyalcohols of high optical purity ARCO CHEMICAL TECHNOLOGY, L.P. (US) 1994-01-11 US disclosed
EP-0454463-A2 Process for producing epoxyalcohols of high optical purity ARCO Chemical Technology, L.P. (US) 1991-10-30 EP disclosed
US-4616086-A ANTICOAGULANTS BOEHRINGER MANNHEIM GMBH (DE) 1986-10-07 US disclosed
EP-0076996-B1 CARBOXYLIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM Roche Diagnostics GmbH (DE) 1986-01-02 EP disclosed
EP-0076996-A1 Carboxylic-acid derivatives, process for their preparation and medicines containing them Roche Diagnostics GmbH (DE) 1983-04-20 EP disclosed
US-4120960-A DIURETICS, SALURESIS THE BOOTS COMPANY LIMITED (GB) 1978-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509791-B2 Formation of organic electro-grafted films on the surface of electrically conductive or semi-conductive surfaces HCN4, EPCAM, KCNN4 ALDH1A1 1289/4885MAPK1 763/4885GSK3B 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.